Literature DB >> 20150630

The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.

Dhana E Larsson1, Malin Wickström, Sadia Hassan, Kjell Oberg, Dan Granberg.   

Abstract

UNLABELLED: The aim of this study was to investigate the apoptosis resulting from NSC 95397, brefeldin A, bortezomib and sanguinarine in neuroendocrine tumor cell lines.
MATERIALS AND METHODS: A multiparametric high-content screening assay for measurement of apoptosis was used. The human pancreatic carcinoid cell line, BON-1, human typical bronchial carcinoid cell line NCI-H727 and the human atypical bronchial carcinoid cell line NCI-H720 were tested. After incubation with cytotoxic drugs, the DNA-binding dye Hoechst 33342, fluorescein-tagged probes that covalently bind active caspase-3 and chloromethyl-X-rosamine to detect mitochondrial membrane potential were added. Image acquisition and quantitative measurement of fluorescence was performed using automated image capture and analysis instrument ArrayScan. In addition, nuclear morphology was examined on microscopic slides stained with May-Grunewald-Giemsa.
RESULTS: A time- and dose-dependent activation of caspase-3 and increase in nuclear fragmentation and condensation were observed for the drugs using a multiparametric apoptosis assay. These results were confirmed with nuclear morphological examination on microscopic slides.
CONCLUSION: NSC 95397, brefeldin A, bortezomib and sanguinarine induced caspase-3 activation with modest changes in nuclear morphology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20150630

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Carbon Monoxide Activates PERK-Regulated Autophagy to Induce Immunometabolic Reprogramming and Boost Antitumor T-cell Function.

Authors:  Paramita Chakraborty; Rasesh Y Parikh; Seungho Choi; Danh Tran; Monika Gooz; Zachariah T Hedley; Do-Sung Kim; Dariusz Pytel; Inhong Kang; Satish N Nadig; Gyda C Beeson; Lauren Ball; Meenal Mehrotra; Hongjun Wang; Stefano Berto; Viswanathan Palanisamy; Hong Li; Shilpak Chatterjee; Paulo C Rodriguez; Eduardo N Maldonado; J Alan Diehl; Vamsi K Gangaraju; Shikhar Mehrotra
Journal:  Cancer Res       Date:  2022-05-16       Impact factor: 13.312

Review 2.  Neuroendocrine differentiation and the ubiquitin-proteasome system in cancer: Partners or enemies?

Authors:  Panagiotis J Vlachostergios; Christos N Papandreou
Journal:  World J Exp Med       Date:  2011-12-20

3.  A mutant of SWAP-70, a phosphatidylinositoltrisphosphate binding protein, transforms mouse embryo fibroblasts, which is inhibited by sanguinarine.

Authors:  Yasuhisa Fukui; Sayoko Ihara
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

Review 4.  Antitumor effects of the benzophenanthridine alkaloid sanguinarine: Evidence and perspectives.

Authors:  Roberta Gaziano; Gabriella Moroni; Cristina Buè; Martino Tony Miele; Paola Sinibaldi-Vallebona; Francesca Pica
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

Review 5.  CtBP- an emerging oncogene and novel small molecule drug target: Advances in the understanding of its oncogenic action and identification of therapeutic inhibitors.

Authors:  M Michael Dcona; Benjamin L Morris; Keith C Ellis; Steven R Grossman
Journal:  Cancer Biol Ther       Date:  2017-05-22       Impact factor: 4.742

6.  mTOR inhibitors activate PERK signaling and favor viability of gastrointestinal neuroendocrine cell lines.

Authors:  Patricia Freis; Julien Bollard; Justine Lebeau; Patrick Massoma; Joëlle Fauvre; Cécile Vercherat; Thomas Walter; Serge Manié; Colette Roche; Jean-Yves Scoazec; Carole Ferraro-Peyret
Journal:  Oncotarget       Date:  2017-03-28

7.  Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2-M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC.

Authors:  Suman Chatterjee; Eric H-B Huang; Ian Christie; Timothy F Burns
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

8.  A decision process for drug discovery in retinoblastoma.

Authors:  María Belen Cancela; Santiago Zugbi; Ursula Winter; Ana Laura Martinez; Claudia Sampor; Mariana Sgroi; Jasmine H Francis; Ralph Garippa; David H Abramson; Guillermo Chantada; Paula Schaiquevich
Journal:  Invest New Drugs       Date:  2020-11-16       Impact factor: 3.850

Review 9.  The transrepression and transactivation roles of CtBPs in the pathogenesis of different diseases.

Authors:  Zhi Chen
Journal:  J Mol Med (Berl)       Date:  2021-07-01       Impact factor: 4.599

Review 10.  Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells.

Authors:  Muhammad Khan; Amara Maryam; Javed Iqbal Qazi; Tonghui Ma
Journal:  Int J Biol Sci       Date:  2015-07-16       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.